Q: I am consideribg buying both and will apreciate your Opinion.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Whatever happened to Automodular? When they were last in the news, they were trying to pivot from auto parts (had just lost the Ford contract) to wind turbine manufacturing. I seem to remember they were left with a sizeable cash pool? With the growing emphasis on wind power, supported by new leadership in the US, are they likely to resurface? The management seemed to be very shareholder-focused.
Q: Could I have your comments on HLS's acquisition of a Portfolio of 4 royalty interests.
Thank-you.
Thank-you.
Q: It's been awhile since you commented Fronsac stock. Last earnings looks very good, they mostly rent to gaz stations, fast foods and some grocery stores. Can you comment earnings?
Also, what is your point of view about HLS Therapeutics considering Vascepa?
Thanks 5i!!!
Also, what is your point of view about HLS Therapeutics considering Vascepa?
Thanks 5i!!!
Q: Hi 5i team!
What is your opinion of HLS these days?
I last asked about them in Feb 2019. At the time you were concerned about their debt level. Has it improved (marginally or otherwise) since then or do you foresee any further improvement in 2020 and beyond based on their recent financials?
They had a good 2019 wrt stock price appreciation.
They have recently received approval from Health Canada re Vascepa but significant sales from that drug may not occur for a year or 2 (or more).
Can this be added to an already diversified portfolio of mid caps? I recently took a 1/4 position in mid Dec at $19.34. I would like to add a further 1/4 position each quarter going forward. This will allow me to monitor their overall progress wrt their additional drug portfolio.
They stated that peak sales of Vascepa may not occur until 2-4 years thus the patient accumulation.
Cheers,
Steve
What is your opinion of HLS these days?
I last asked about them in Feb 2019. At the time you were concerned about their debt level. Has it improved (marginally or otherwise) since then or do you foresee any further improvement in 2020 and beyond based on their recent financials?
They had a good 2019 wrt stock price appreciation.
They have recently received approval from Health Canada re Vascepa but significant sales from that drug may not occur for a year or 2 (or more).
Can this be added to an already diversified portfolio of mid caps? I recently took a 1/4 position in mid Dec at $19.34. I would like to add a further 1/4 position each quarter going forward. This will allow me to monitor their overall progress wrt their additional drug portfolio.
They stated that peak sales of Vascepa may not occur until 2-4 years thus the patient accumulation.
Cheers,
Steve
Q: your thoughts on recent Q3 results. worth sticking with this company or can you suggest alternative investment.
thanks
Don
thanks
Don
Q: I've been a longtime holder of GUD but have become somewhat frustrated at the lack of growth. I'm wondering what your thoughts are about splitting my Knight holdings and placing them in HRX and HLS. Is there a decent risk/reward scenario here? Both companies are near 52 week highs but seem to be somewhat under reported.
Thank you for a fantastic service!
Mike
Thank you for a fantastic service!
Mike
Q: Hi, I received shares in this company (HLS) via a reverse takeover of ADM (Automodular) back in late '17.
I don't see any other questions on this company thus the inquiry. What is your valued opinion of HLS?
From their web page...'HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. '
They seem to have a couple of drugs Vascepa, Clozaril and Absorica that are or will generate decent revenues going forward.
They also introduced a quarterly dividend recently and I know you favour companies when this occurs.
Are they a 'show me' story right now and patience is required for a couple quarters to see how they proceed, ie it looks like they will be filing for approval with Health Canada in early 2019 for Vascepa (it's already FDA approved).
Analysts targets are for around $20 for 2019 (from your 'Companies' page).
Cheers,
Steve
I don't see any other questions on this company thus the inquiry. What is your valued opinion of HLS?
From their web page...'HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. '
They seem to have a couple of drugs Vascepa, Clozaril and Absorica that are or will generate decent revenues going forward.
They also introduced a quarterly dividend recently and I know you favour companies when this occurs.
Are they a 'show me' story right now and patience is required for a couple quarters to see how they proceed, ie it looks like they will be filing for approval with Health Canada in early 2019 for Vascepa (it's already FDA approved).
Analysts targets are for around $20 for 2019 (from your 'Companies' page).
Cheers,
Steve